1- [2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition

Details for Australian Patent Application No. 2008228638 (hide)

Owner H. Lundbeck A/S

Inventors Stensbol, Tine Bryan; Moore, Nicholas

Agent Spruson & Ferguson

Pub. Number AU-B-2008228638

PCT Pub. Number WO2008/113359

Priority PA 200700427 20.03.07 DK; PCT/ DK2007/050075 15.06.07 DK

Filing date 14 March 2008

Wipo publication date 25 September 2008

Acceptance publication date 20 September 2012

International Classifications

C07D 295/08 Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

A61K 31/495 - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61P 25/04 Drugs for disorders of the nervous system

A61P 25/22 Drugs for disorders of the nervous system

A61P 25/24 Drugs for disorders of the nervous system

A61P 25/26 Drugs for disorders of the nervous system

A61P 25/28 Drugs for disorders of the nervous system

Event Publications

15 October 2009 PCT application entered the National Phase

  PCT publication WO2008/113359 Priority application(s): WO2008/113359

20 September 2012 Application Accepted

  Published as AU-B-2008228638

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008228639-4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistent depression or residual symptoms in depression

2008228637-Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)phenyl]pip eridine